HIF-1α: a Potential Treatment Target in Chronic Lymphocytic Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2020 Apr 3

PMID 32238465

Citations 6

Authors

Martina Seiffert

Affiliations

Soon will be listed here.

Citing Articles

MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.

Golovina E, Heizer T, Daumova L, Bajecny M, Fontana S, Griggio V Cancer Cell Int. 2024; 24(1):251.

PMID: 39020347 PMC: 11256420. DOI: 10.1186/s12935-024-03437-8.

Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia.

Pandey S, Singh R, Habib N, Tripathi R, Kushwaha R, Mahdi A Asian Pac J Cancer Prev. 2024; 25(4):1121-1134.

PMID: 38679971 PMC: 11162727. DOI: 10.31557/APJCP.2024.25.4.1121.

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies.

Zhao Y, Xing C, Deng Y, Ye C, Peng H Genes Dis. 2023; 11(1):234-251.

PMID: 37588219 PMC: 10425810. DOI: 10.1016/j.gendis.2023.02.039.

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.

Mancikova V, Pesova M, Pavlova S, Helma R, Zavacka K, Hejret V Mol Oncol. 2022; 17(1):82-97.

PMID: 36334078 PMC: 9812841. DOI: 10.1002/1878-0261.13337.

Roles of lncRNA LVBU in regulating urea cycle/polyamine synthesis axis to promote colorectal carcinoma progression.

Meng X, Peng J, Xie X, Yu F, Wang W, Pan Q Oncogene. 2022; 41(36):4231-4243.

PMID: 35906392 PMC: 9439952. DOI: 10.1038/s41388-022-02413-8.

References

Yosifov D, Idler I, Bhattacharya N, Reichenzeller M, Close V, Ezerina D . Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia. 2019; 34(1):115-127. DOI: 10.1038/s41375-019-0513-x. View

Tausch E, Beck P, Schlenk R, Jebaraj B, Dolnik A, Yosifov D . Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica. 2020; 105(10):2440-2447. PMC: 7556677. DOI: 10.3324/haematol.2019.229161. View

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C . HIF-1α is over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica. 2019; 105(4):1042-1054. PMC: 7109756. DOI: 10.3324/haematol.2019.217430. View

Hanna B, Ozturk S, Seiffert M . Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. Mol Immunol. 2017; 110:77-87. DOI: 10.1016/j.molimm.2017.11.014. View

Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C . HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood. 2016; 127(16):1987-97. PMC: 4946537. DOI: 10.1182/blood-2015-07-657056. View

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S . BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2014; 2(5):611-24. PMC: 3892793. DOI: 10.1002/cam4.112. View

Schockel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G . Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 2015; 3:11. PMC: 4615872. DOI: 10.1186/s40170-015-0138-0. View

Koczula K, Ludwig C, Hayden R, Cronin L, Pratt G, Parry H . Metabolic plasticity in CLL: adaptation to the hypoxic niche. Leukemia. 2015; 30(1):65-73. PMC: 4705428. DOI: 10.1038/leu.2015.187. View

Madan E, Parker T, Pelham C, Palma A, Peixoto M, Nagane M . HIF-transcribed p53 chaperones HIF-1α. Nucleic Acids Res. 2019; 47(19):10212-10234. PMC: 6821315. DOI: 10.1093/nar/gkz766. View

10.

Hammond E, Giaccia A . The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005; 331(3):718-25. DOI: 10.1016/j.bbrc.2005.03.154. View

11.

Lamb J, Crawford E, Peck D, Modell J, Blat I, Wrobel M . The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313(5795):1929-35. DOI: 10.1126/science.1132939. View

12.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

13.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen S . Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2018; 1(1):47-61. PMC: 5744057. DOI: 10.1182/bloodadvances.2016000984. View

14.

Sanchez-Puig N, Veprintsev D, Fersht A . Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell. 2005; 17(1):11-21. DOI: 10.1016/j.molcel.2004.11.019. View

15.

Ghosh A, Shanafelt T, Cimmino A, Taccioli C, Volinia S, Liu C . Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009; 113(22):5568-74. PMC: 2689054. DOI: 10.1182/blood-2008-10-185686. View

16.

Close V, Close W, Kugler S, Reichenzeller M, Yosifov D, Bloehdorn J . mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood. 2018; 133(8):830-839. DOI: 10.1182/blood-2018-09-874529. View

17.

Bhattarai D, Xu X, Lee K . Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A "structure-activity relationship" perspective. Med Res Rev. 2017; 38(4):1404-1442. DOI: 10.1002/med.21477. View